openPR Logo
Press release

Biosimilars Market: Analysis of Rising Business Opportunities with Prominent Investment Ratio by Key Players: Novartis, Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd.

12-17-2018 09:27 AM CET | Health & Medicine

Press release from: Allied Market Research

Biosimilars Market

Biosimilars Market

Allied Market Research recently published a report, titled, “Biosimilars Market (Follow-on-Biologics) by Types (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, Peptide) and Application (Blood disorders, Oncology diseases, Growth hormone deficiencies): Global Opportunity Analysis and Industry Forecast, 2014–2020”. According to the report, the global biosimilars market accounted for $2.55 billion in 2014 and is estimated to garner $26.55 billion by 2020, registering the CAGR of 49.1% from 2014 to 2020.

This report provides a comprehensive market share analysis of leading companies and highlights the competition in the market. Product launch is the key strategy adopted by the leading player of biosimilars industry. The key companies profiled in this report are Novartis (Sandoz), Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec, Inc., and Genentech (Roche Group).

Get Sample PDF Brochure : https://www.alliedmarketresearch.com/request-sample/700

Increased healthcare expenditure, high prevalence of chronic diseases among geriatric population, and low cost of biosimilar drugs compared to original biologics have boosted the growth of the global biosimilar market. However, high initial investment in R&D and stringent regulation in the developed countries to restrict investment hinders the market growth. On the contrary, rise in awareness about biosimilars in emerging markets is expected to create remunerative opportunities for the market players in the coming years.
Recent approval of Zarxio (filgrastim-sndz) as first biosimilar by U.S. FDA has opened new opportunities for biosimilar manufactures. Patents for number of blockbuster bio-pharmaceuticals have either expired or are on the verge of expiration, which is majorly driving the growth of biosimilars industry. Changes in regulatory guidelines and convenient biosimilar drug approval processes have a major impact on the commercial growth of global biosimilars market.

Europe would continue to dominate the market while the Asia–Pacific would emerge as the fastest growing region over the forecast period.
Glycosylated proteins namely, erythropoietin and monoclonal antibodies are the leading biosimilar segments commercially available across the globe, together accounting for about one-third of the market revenue in 2014. This significant hold in the market is chiefly due to its large application in the treatment of chronic conditions such as blood-related disorders, cancer, among others.

Key findings of Global Biosimilars Market:

• The biosimilar applications in blood disorders and oncology collectively evaluated at 61% in 2014
• Interferon is the fastest growing biosimilar, expected to grow at a CAGR of 51.1% during the forecast period
• U.S. would find space in the biosimilar market with a single-digit revenue share of overall biosimilar market by 2020

European region is the leading beneficiary of biosimilars market and is attracting investors, interested in biosimilars industry. The prospects in the European region are largely supplemented by the presence of streamlined regulatory guidelines and a high level of adoption for biosimilars among physicians. The establishment of favorable regulations such as Article 10(4) of Directive 2001/83/EC by the European Medical Association (EMA) has clarified the clinical aspect of biosimilars. This standard set by EMA has attracted investors to invest into the development of biosimilars. The Asia-Pacific region projects the fastest growth rate, supplemented by the high prevalence of chronic diseases and the growing demand for economic bio-pharmaceuticals. The commercial scenario of biosimilars in North America is bleak due to the absence of regulations for approval and commercialization. However, after the launch of the first biosimilar in United States, the investors are now focusing on this region to boost their prospects.

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David C
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilars Market: Analysis of Rising Business Opportunities with Prominent Investment Ratio by Key Players: Novartis, Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd. here

News-ID: 1443600 • Views:

More Releases from Allied Market Research

Home Exercise Bike Market is expected to witness robust Compound Annual Growth Rate (CAGR) progress of 8.7% from 2021 to 2027.
Home Exercise Bike Market is expected to witness robust Compound Annual Growth R …
According to a new report published by Allied Market Research, titled, "Home Exercise Bike Market by Type, and Sales Channel: Opportunity Analysis and Industry Forecast, 2021-2027," The global home exercise bike market size was valued at $1,213.5 million in 2019, and is projected to reach $2,335.2 million by 2027, registering a CAGR of 8.7% from 2021 to 2027. The recumbent segment is expected to retain its dominant position, in terms
Rapidly expanding entertainment products industry is set to drive the growth of the $103.8 billion Toys market ; Ravensburger AG, Tomy Company, Ltd, Vtech Holdings, and Thames & Kosmos.
Rapidly expanding entertainment products industry is set to drive the growth of …
According to a new report published by Allied Market Research, titled, "Toys Market by Product Type, Age Group and Sales Channel: Opportunity Analysis and Industry Forecast, 2021-2027," the toys market size was $92.2 billion in 2019, and is projected reach $103.8 billion by 2027, registering a CAGR of 2.5% from 2021 to 2027. The increase in number of games bars, cafes and family entertainment centers worldwide is boosting the demand for
Global Home Beer Brewing Machine Market is expected to reach $25.4 million by the year 2030, as projected by Allied Market Research.
Global Home Beer Brewing Machine Market is expected to reach $25.4 million by th …
According to a new report published by Allied Market Research, titled, "home beer brewing machine market by product type, mechanism, and distribution channel: global opportunity analysis and industry forecast, 2021-2030," The global home beer brewing machine market size was valued at $19.1 million in 2020, and is projected to reach $25.4 million by 2030, registering a CAGR of 3.0% from 2021 to 2030. Request a report sample to gain comprehensive insights
Hospitality Robots Market is forecasted to grow at a Compound Annual Growth Rate (CAGR) of 25.5% through the year 2030, according to Allied Market Research.
Hospitality Robots Market is forecasted to grow at a Compound Annual Growth Rate …
According to a new report published by Allied Market Research, titled, "Hospitality Robots Market by Type, End User, Sales Channel and Region: Global Opportunity Analysis and Industry Forecast, 2021-2030," The global hospitality robots market size is expected to reach $3,083 million by 2030 at a CAGR of 25.5% from 2021 to 2030. Hospitality Robots Market by Type (Front Desk Robots, Delivery Robots, Cleaning Robots and Others) and end user (Hotels,

All 5 Releases


More Releases for Biosimilars

Global Biosimilars Market 2021-2028 | Price Advantage of Biosimilars Over Biolog …
The global Biosimilars market focuses on encompassing major statistical evidence for the Biosimilars industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition, the Biosimilars study also shifts its attention with an in-depth
Growth of the Biosimilars Market Is Mainly Driven by Increasing Number of Approv …
A biosimilar is a biologic medical product that is similar to another already approved biological medicine, in terms of quality, safety, and efficacy. Biosimilars are a class of therapeutic drugs that provide additional treatment options and help reduce healthcare costs. Thus, there is an increasing demand for biosimilar drugs due to increasing prevalence of autoimmune diseases, key factor driving the growth of the biosimilars market. According to the National Stem
Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure. According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased. According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was
Global Oral Biologics and Biosimilars Market | Global Oral Biologics and Biosimi …
The oral biologics and biosimilar market contain of sales of oral biologics and biosimilar products and associated services utilized to treat chronic syndromes such as diabetes, arthritis, cancer. Biologics are drugs completed from living cells using exceedingly complex technology while biosimilars are generated to function similarly to biologics but are not matching to biologics. Biosimilars offer energetic properties as any licensed biologic drug. The oral biologics and biosimilar market encompass
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million